Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

30.48

Today's Change

+0.98 (3.32%)

Day's Change

29.50 - 30.88

Trading Volume

3,161,486

Overview

Market Cap

3 Billion

Shares Outstanding

111 Million

Avg Volume

3,803,416

Avg Price (50 Days)

39.32

Avg Price (200 Days)

55.64

PE Ratio

-30.18

EPS

-1.01

Earnings Announcement

22-Apr-2025

Previous Close

29.50

Open

29.64

Day's Range

29.5 - 30.8799

Year Range

28.64 - 99.41

Trading Volume

3,184,339

Price Change Highlight

1 Day Change

3.32%

5 Day Change

-6.90%

1 Month Change

-12.56%

3 Month Change

-38.52%

6 Month Change

-46.53%

Ytd Change

-25.88%

1 Year Change

-4.30%

3 Year Change

706.35%

5 Year Change

350.89%

10 Year Change

281.00%

Max Change

281.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment